Attention deficit hyperactivity disorder

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Retrieved on: 
Monday, April 1, 2024
Research, ADHD, Psych, NDA, Sale, Cingulata, Attention deficit hyperactivity disorder, Insurance, IND, Market, Adolescence, Safety, Clutch (eggs), Poster, WFIA, FDA, Security (finance)

KANSAS CITY, Kan., April 01, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the twelve months ended December 31, 2023, and provided a clinical and business update. Highlights include capital raised from multiple sources and the addition of three independent board members.

Key Points: 
  • “Our lead asset CTx-1301 continues to impress clinical investigators and key opinion leaders as we share our Phase 3 results.
  • These tailwinds put Cingulate in a position to obtain non-dilutive capital and expand our pipeline of assets.
  • Looking ahead, Cingulate has several financial instruments in place to raise additional capital while fighting to preserve shareholder’s equity.
  • “Overall, I am very pleased with the progress made by our team in 2023 and into 2024.

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

Retrieved on: 
Thursday, March 14, 2024
SIV, Data, Combination, EGFR, Property, SPI, Patient, Sale, Attention deficit hyperactivity disorder, Syndrome, Lung cancer, IND, Myelodysplastic syndrome, Bank statement, Investment, Note, European, TNBC, ADHD, GAP, BioLite, DSM-IV codes, GMP, Investigational New Drug, MDS, Common stock, UCSF, NSCLC, Dietary supplement, Research, Good manufacturing practice, Cancer, University, Security (finance), Pancreatic cancer, Drug development, TGA, FDA, Map, Consultant, Variable, Toxicity, Metastasis, Patent, MDD, Triple-negative breast cancer, License, Long-term care, Net, US FDA, Pharmaceutical industry

As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).

Key Points: 
  • As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).
  • The Company entered a cooperation agreement on August 14, 2023, with Zhong Hui Lian He Ji Tuan, Ltd. (“Zhonghui”).
  • On February 06, 2024, ABVC acquired an additional real estate asset via an equity transfer of 703,495 shares at $3.50 per share to develop plant factories for ABVC’s botanical pipeline.
  • ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries.

Student-Athletes with Self-Reported Autism Spectrum Disorder are More Likely to Score Low on Common Concussion Test, Raising the Need for Autism-Specific Comparison Data

Retrieved on: 
Thursday, March 28, 2024
Research, School, Immediate, Archive, Learning, Saint Joseph's University, Impact, ADHD, Prevalence, Exercise, DSM-IV codes, Support, Concussion, University, Doctor of Philosophy, Athlete, Attention deficit hyperactivity disorder, Psychology, Neuropsychology, Spectrum, Multimedia, FDA, ASD, Medicine, Dietary supplement

PHILADELPHIA, March 28, 2024 /PRNewswire/ -- Schools and colleges across the country rely on Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) evaluations to assess and manage student-athlete concussions on the sidelines. However, this FDA-cleared tool is not recommended for student-athletes with neurodevelopmental disorders, who often score significantly lower than neurotypical individuals. New research published Feb. 13 in the Archives of Clinical Neuropsychology demonstrates the need for alternative or modified concussion assessment norms and the need for baseline testing for autistic athletes.

Key Points: 
  • However, this FDA-cleared tool is not recommended for student-athletes with neurodevelopmental disorders, who often score significantly lower than neurotypical individuals.
  • "The [neuropsychology] field needs to expand assessment and interpretation practices and procedures for people with ASD and related developmental conditions."
  • Individuals with attention deficit hyperactivity disorder (ADHD), learning disorder (LD) and ASD are not included in normative reference data.
  • This means when autistic athletes are assessed for a concussion, their data is compared to age- and gender-similar neurotypical individuals.

Parental avoidance of toxic exposures could help prevent autism, ADHD in children, new study shows

Retrieved on: 
Thursday, March 28, 2024
Pesticide, Sensitivity, Xenobiotic, Collaborative writing, Prevalence, ADHD, Cell, Risk, Inflammation, Patient, SAN, School, Anglo-French Wars, Tissue, Research, Miller, Child, Breast, Virus, University, Wane, Doctor of Philosophy, Pregnancy, Causality, Attention deficit hyperactivity disorder, Gulf War, B cell, EPA, CDC, University of Texas System, Fire, Toxicology, Workforce, Public health, TILT, Spectrum, Family, Histamine, Vaccine

SAN ANTONIO, March 27, 2024 /PRNewswire-PRWeb/ -- Autism and attention deficit hyperactivity disorder (ADHD) may be preventable if parents avoid toxic exposures and adopt interventions such as environmental house calls, according to a published study led by researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio).

Key Points: 
  • The findings build on a 2015 study by UT Health San Antonio that first linked chemical intolerance in patients with the risk of their children developing autism and ADHD.
  • "Up to now, most interventions have been behavioral or medical, after a child is diagnosed."
  • Still, they wrote, "The implications of this study, if confirmed, could be significant for preventive measures and early intervention strategies in families with parental chemical intolerance.
  • And the prevalence of ADHD has risen to one in eight children, also according to the CDC.

Government Employees Have Low Awareness of Neurodiversity in the Workplace, According to New Eagle Hill Consulting Research

Retrieved on: 
Wednesday, March 20, 2024
Government, Culture, Tourette syndrome, Communication, Thought, Box, Federation, Ipsos, Dyscalculia, Research, Neurodiversity, Time management, Attention deficit hyperactivity disorder, Strategy, Dyslexia, Workforce, Multimedia, Workplace, Developmental coordination disorder, Management

ARLINGTON, Va., March 20, 2024 /PRNewswire/ -- Sixty-one percent of government employees either said they are unfamiliar with the term neurodiversity or don't know its meaning, according to new research from Eagle Hill Consulting. While 85 percent of government employees say they would hire, or have hired, a neurodivergent employee, few are trained on working with or managing neurodivergent workers. 

Key Points: 
  • ARLINGTON, Va., March 20, 2024 /PRNewswire/ -- Sixty-one percent of government employees either said they are unfamiliar with the term neurodiversity or don't know its meaning, according to new research from Eagle Hill Consulting .
  • Jezior added, "It's encouraging to see that government employees are more cognizant of neurodiversity as compared to private sector workers.
  • In a new national poll of government employees , Eagle Hill found:
    Sixty percent of government employees say training in sensitivity to social differences would be valuable, and 62 percent indicated they would be interested in training on managing neurodivergent employees.
  • These findings are from the Eagle Hill Consulting Neurodiversity in Government Survey conducted by Ipsos from January 11-18, 2024.

New Eagle Hill Consulting Research Finds U.S. Employees Have Low Awareness of Neurodiversity in the Workplace

Retrieved on: 
Monday, March 18, 2024
Culture, Organization, Tourette syndrome, Ipsos, Dyscalculia, Research, News, Neurodiversity, Time management, Condition, Attention deficit hyperactivity disorder, Strategy, Dyslexia, Workplace, Potential, Multimedia, Developmental coordination disorder, Management

ARLINGTON, Va., March 18, 2024 /PRNewswire/ -- Sixty-eight percent of U.S. employees either said they are unfamiliar with the term neurodiversity or don't know its meaning, according to new research from Eagle Hill Consulting. While 72 percent of employees say they would hire a neurodivergent employee, few workers are trained on working with or managing neurodivergent workers. 

Key Points: 
  • These findings are detailed in a new report, Neurodiversity in the Workplace : Are Organizations Overlooking Their Highly Capable Neurodivergent Employees When Creating the Conditions for Corporate Success?
  • The new Eagle Hill research finds that when evaluating employee performance, most consider the ability to communicate clearly (55 percent) and stay organized (54 percent), as important evaluation criteria, skills that often are challenging for neurodivergent employees.
  • These findings are from the Eagle Hill Consulting Neurodiversity in the Workplace Survey conducted by Ipsos from January 11-18, 2024.
  • Eagle Hill Consulting LLC is a woman-owned business that provides unconventional management consulting services in the areas of Strategy & Performance, Talent, and Change.

MEDIA ENTREPRENEUR AND CLIMATE LEADER CHIP GILLER AND PHILANTHROPIST WENDY SCHMIDT LAUNCH AGOG, AN IMMERSIVE MEDIA INSTITUTE FOR SOCIAL GOOD

Retrieved on: 
Monday, March 11, 2024
Narrative, Anagram, Climate change, Education, Sound, Forager, Communication, Lifting, Grist, Empathy, XR, The Sleepover Club, Blue, Social impact, City, Boy, Policy, University, Immersion (virtual reality), Social justice, Attention deficit hyperactivity disorder, Reality, System, Social change, Journalism, Virtual reality

AUSTIN, Texas, March 11, 2024 /PRNewswire/ -- Chip Giller and Wendy Schmidt announced today the launch of Agog: The Immersive Media Institute—a groundbreaking initiative at the intersection of technology, communications, and social impact. Agog, a philanthropic organization, will help creators and nonprofit leaders harness the power of extended reality (XR) technologies to spur positive social transformation, opening new avenues for empathy, understanding, and activism.

Key Points: 
  • AUSTIN, Texas, March 11, 2024 /PRNewswire/ -- Chip Giller and Wendy Schmidt announced today the launch of Agog: The Immersive Media Institute—a groundbreaking initiative at the intersection of technology, communications, and social impact.
  • Research: The institute will partner with researchers to explore the applications of XR in fostering empathy and driving positive behavioral change.
  • Education and outreach: Through workshops, technical support, training programs, and other outreach initiatives, the institute will empower people to use XR for social good.
  • Advocacy and policy: The institute will engage in efforts to promote responsible and ethical use of immersive media technologies.

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 5, 2024
PD, Research, FDA, ATM, Food, Growth, Anaphylaxis, Loss, PDUFA, Attention deficit hyperactivity disorder, Emergency, Safety, Therapy, Allergy, Patent, Diazepam, Patient, Serdexmethylphenidate/dexmethylphenidate, Lennox–Gastaut syndrome, Net, ADHD, Adrenaline, Clutch (eggs), Trial of the century, NDA, Riluzole, Seizure, Pharmaceutical industry

Aquestive received positive feedback in October 2023 from the U.S. Food and Drug Administration (FDA) on the Company's pivotal Phase 3 Pharmacokinetic (PK) clinical protocol for Anaphylm.

Key Points: 
  • Aquestive received positive feedback in October 2023 from the U.S. Food and Drug Administration (FDA) on the Company's pivotal Phase 3 Pharmacokinetic (PK) clinical protocol for Anaphylm.
  • Aquestive commenced dosing in December 2023 in the Phase 3 pivotal PK clinical study of Anaphylm.
  • Non-GAAP adjusted EBITDA loss was $2.8 million in the fourth quarter 2023, compared to a $9.6 million loss in the fourth quarter 2022.
  • During the fourth quarter 2023, the Company accessed capital net proceeds of $3.7 million under its "At-the-Market" (ATM) facility.

Firefly Neuroscience’s White Paper Unveils BNA™ Platform’s Significant Impact on Disease Management in 2,253 U.S Patients

Retrieved on: 
Tuesday, March 5, 2024
BNA, Transcranial magnetic stimulation, My Little Pony, AI, FDA, WAVD, Psychiatry, GAD, Antidepressant, EEG, Patient, Attention deficit hyperactivity disorder, DSM-IV codes, ADHD, MDD, Depression

FAIRFAX, Va. and TORONTO, March 05, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”), a pioneering AI company developing innovative neuroscientific solutions to improve outcomes for patients with mental illnesses and neurological disorders, today announced the findings presented in a 2023 white paper “Brain Network Analytics (BNA) in the Psychiatric Practice: Real-Life Data Analysis” by Charlotte Baumeister, Ph.D., with analysis by Offir Laufer, Ph.D. Firefly has entered into an agreement (as amended, the “Merger Agreement”) to merge with WaveDancer, Inc. (“WaveDancer”) (NASDAQ: WAVD), subject to the approval of the stockholders of Firefly and WaveDancer (the “Merger”).

Key Points: 
  • This FDA-approved 510(k) tool harnesses vast data sets, including thousands of normative, age-matched electroencephalogram (“EEG”) recordings, empowering clinicians to make informed decisions in therapy and disease management.
  • The results suggest the transformative potential of the BNA™ Platform to significantly improve psychiatric care.
  • With the potential to revolutionize disease management, enhance treatment outcomes, and improve the overall well-being of patients with mental illnesses and cognitive disorders, we believe the BNA™ Platform can have a transformative impact.
  • We believe these findings will pave the way for widespread adoption of the BNA™ Platform into standard patient management protocols.”

Supernus Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
Central nervous system, Topiramate, Investigational New Drug, PD, Total, New Drug Application, FDA, Food, Growth, PDUFA, Safety, GAAP, CNS, Depreciation, IQVIA, Patient, AISRS, Attention deficit hyperactivity disorder, DSM-IV codes, ADHD, Phase, MDD, Prescription, MADRS, Pharmaceutical industry

ROCKVILLE, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the fourth quarter and full year of 2023 and associated Company developments.

Key Points: 
  • Fourth quarter 2023 net sales of Qelbree® increased 97% to $46.4 million compared to fourth quarter 2022; Full year 2023 net sales of Qelbree increased 129% to $140.2 million compared to full year 2022.
  • Fourth quarter 2023 net sales of GOCOVRI® increased 10% to $32.0 million compared to fourth quarter 2022; Full year 2023 net sales of GOCOVRI increased 15% to $119.6 million compared to full year 2022.
  • Full year 2023 operating loss (GAAP) was $(5.3) million; Full year 2023 operating earnings (non-GAAP)(2), were $125.1 million.
  • ROCKVILLE, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the fourth quarter and full year of 2023 and associated Company developments.